An Open-Label Study to Evaluate the Effect of a Single Dose of Briakinumab on the Pharmacokinetics of Single Doses of Caffeine, Tolbutamide, Omeprazole, Metoprolol, and Midazolam in Subjects With Moderate to Severe Psoriasis.

Trial Profile

An Open-Label Study to Evaluate the Effect of a Single Dose of Briakinumab on the Pharmacokinetics of Single Doses of Caffeine, Tolbutamide, Omeprazole, Metoprolol, and Midazolam in Subjects With Moderate to Severe Psoriasis.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2011

At a glance

  • Drugs Briakinumab; Caffeine; Metoprolol; Midazolam; Omeprazole; Tolbutamide
  • Indications Plaque psoriasis
  • Focus Pharmacokinetics
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 10 Aug 2011 Planned end date changed from 1 Mar 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 10 Aug 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 10 Aug 2011 Actual initiation date (Apr 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top